Renal Carcinoid Tumor Metastatic to the Uvea, Medial Rectus Muscle, and the Contralateral Lacrimal Gland.
Renal carcinoid tumor is an exceedingly rare malignancy. A 57-year-old man with a renal carcinoid tumor discovered after metastasizing to intraocular and bilateral orbital structures is described. The patient presented with a blind painful OS and a right superotemporal subconjunctival mass. Imaging studies revealed a large left intraocular tumor, a mass in the left medial rectus muscle, and right lacrimal gland enlargement. The OS was enucleated, and incisional biopsies were performed from the other 2 lesions. Histopathological studies demonstrated metastatic neuroendocrine tumor with chromogranin and synaptophysin positivity. Systemic work up revealed a right renal mass and multiple hepatic metastatic lesions. Radical nephrectomy was performed, and octreotide, capecitabine, and temozolomide were administered. Removal of the primary tumor and the eye that had no prospect for useful vision and further treatment with octreotide, capecitabine, and temozolomide provided a disease progression-free period of 24 months and allowed the patient to function normally.
*Ocular Oncology Service, Department of Ophthalmology, and †Department of Pathology, Hacettepe University School of Medicine, Ankara, Turkey.
Hayyam
H
Kiratli
Salih
S
Uzun
Berçin
B
Tarlan
Deniz
D
Ateş
Dilek Ertoy
DE
Baydar
Figen
F
Söylemezoğlu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D000069287:Capecitabine / Q000008:administration & dosage; D002276:Carcinoid Tumor / Q000378:metabolism / Q000556:secondary* / Q000628:therapy; D053379:Chromogranin A / Q000378:metabolism; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D015353:Eye Enucleation; D005134:Eye Neoplasms / Q000378:metabolism / Q000556:secondary / Q000628:therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D007766:Lacrimal Apparatus Diseases / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D019042:Muscle Neoplasms / Q000378:metabolism / Q000556:secondary* / Q000628:therapy; D009392:Nephrectomy; D015282:Octreotide / Q000008:administration & dosage; D009801:Oculomotor Muscles / Q000473:pathology*; D016708:Synaptophysin / Q000378:metabolism; D000077204:Temozolomide; D014604:Uveal Neoplasms / Q000378:metabolism / Q000556:secondary* / Q000628:therapy
D014408:Biomarkers, Tumor; C506150:CHGA protein, human; D053379:Chromogranin A; C569014:SYP protein, human; D016708:Synaptophysin; D000069287:Capecitabine; D003606:Dacarbazine; D015282:Octreotide; D000077204:Temozolomide